All In MedTech

Device Trial Radar · NCT05845710

Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)

Protection Against Emboli During caRotid Artery Stenting Using a Neuroguard IEP® Direct 3-in-1 Delivery System Comprised oF a pOst-dilation Balloon, integRated eMbolic Filter, and A Novel Carotid stEnt - the PERFORMANCE III Study

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

178

Actual

Start

Oct 5, 2023

Primary completion

Aug 12, 2025

Study completion Aug 12, 2025

Sponsor

Lead sponsor
Contego Medical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Yale Cardiovascular Research Group; CardioMed Device Consultants, LLC; Advance Research Associates; iMedNet; AG Mednet
First posted
May 6, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 20 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 82 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid arteries (ICA) or at the carotid bifurcation with greater than or equal to 50% stenosis if symptomatic or greater than or equal to 70% stenosis if asymptomatic.

Conditions

  • Carotid Stenosis
  • Carotid Artery Diseases

Interventions

  • Neuroguard IEP Direct SystemDevice

    carotid artery stenting, direct access with blood flow redirection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Major Adverse Events (MAE)Time frame: Within 30 days of the study procedure

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.